Author's posts
The Antihistamine Benadryl Isn’t Being Removed In The U.S. From Pharmacies As An OTC Product
FDA advisory committee vote on ineffectiveness of phenylephrine as nasal decongestant doesn’t mean that the antihistamine Benadryl will be affected.
Pharmaceutical Innovativeness Is Highly Varied, As CMS Will Soon Find Out When It Does Comparative Effectiveness Assessments
Not all of drug innovations are created equal. Some aren’t better than existing standards of care. Others are breakthroughs. Still others are marginal improvements.
Kim Kardashian’s Promotion Of Full-Body Scans Raises Questions About Social Media Influence In Healthcare
Whichever drug or diagnostic, consumers and patients should be looking to learned intermediaries, such as their doctors, for health advice and not celebrity influencers.
Inflation Reduction Act May Accelerate Generic And Biosimilar Market Entry, But Questions Remain Around CMS Guidance
The IRA may alter the incentives drug firms have to pursue evergreening strategies, as having generic or biosimilar competition can exempt a drug from price negotiation.
CMS Faces Major Challenges As It Establishes Itself As A Health Technology Assessment Entity In The Wake Of The IRA
As CMS establishes itself as an HTA entity, it may consider carving out the HTA function and delegating it to an external entity that can operate as a neutral arbiter.
The List Of 10 Drugs Medicare Will Negotiate Prices Of Contains A Few Surprises
Conspicuously, CMS included drugs that could face imminent generic or biosimilar competition before 2026, which is when the negotiated prices first go into effect.
Latest Covid Wave Driven By Eris (EG.5), But Pirola (BA.2.86) Is Waiting In The Wings
just as the world may be getting used to seeing Eris (EG.5) gain steam, BA.2.86, dubbed Pirola, may be hot on its heels as the next concerning sub-variant of Omicron.
Nearly Half Of Americans Polled Want Weight Loss Drugs But Many Lose Interest After Reading The Fine Print
While the market for weight loss drugs has potential, questions are raised concerning the drugs’ route of administration, side effect profile, cost and lack of coverage.
On 1-Year Anniversary Of Inflation Reduction Act’s Signing, Impact On Drug Prices And Out-Of-Pocket Spending Still To Be Determined
On the one-year anniversary of the IRA’s signing, most of the bill’s impact on drug prices and Medicare beneficiary out-of-pocket spending has yet to be determined.
Topline Data On Obesity Drug Wegovy’s Impact On Cardiovascular Outcomes Won’t Necessarily Change Payer Coverage Policies
Topline data from the SELECT trial look good. But this may not necessarily change payer coverage policies on weight loss agents, at least not in the short term.
